Category: featured

Today, COVID-19 is defining our lives. The coronavirus disease outbreak has caught us by surprise resulting in many causalities and economic damage. As of today, more than 1,4 million coronavirus cases have occurred in approx. 200 countries. More than 82 thousand patients have died as a result of this viral infection. Undoubtedly, COVID-19 will change […]

Victor Schut has been appointed as the new Chief Executive Officer (CEO) of AGILeBiotics and co-founder Dr. Andreas A. Bastian has now taken on the role of Chief Operating Officer (COO). Currently raising Series A investment, the appointments come in line with the company’s plans and development strategy.

We are proud to announce that AGILeBiotics is the winner of the Investors Forum 2019, which took place at the Dutch Life Sciences Conference in Leiden on November 28th. During the conference AGILeBiotics has introduced its drug pipeline emphasizing the pre-clinical candidate TOFRAMICIN, a novel antibiotic candidate in development against multidrug-resistant Gram-negative and Gram-positive bacterial […]

We are proud to announce that AGILeBiotics has been awarded the European Soft Matter Infrastructure (EUSMI) grant from from the European Union’s Horizon 2020 research and innovation programme. EUSMI-H2020 provides the community of European soft-matter researchers with an open-access infrastructure as a platform to support and extend their research, covering characterization, synthesis, and modeling. Since […]

We are proud to announce that AGILeBiotics has been awarded the Lead Development Voucher by the Netherlands Antibiotic Development Platform (NADP). The total amount of €50.000 will be allocated to the pre-clinical R&D activities. With this financial support we will evaluate the in vivo efficacy of our antibiotic candidates in a clinically relevant animal model […]

We are proud to announce that AGILeBiotics has expended its Management Team and Scientific Advisory Board. Victor Schut is the new Chief Business Officer, Dr. Frederik Deroose has joined us as expert in pre-clinical development of novel antibiotics, and Prof. Jan Verhoef is now a member of our Scientific Advisory Board. With joined forced we aim to […]

We are proud to announce that AGILeBiotics is now a member of the BEAM Alliance, the European AMR innovation hub gathering Biopharma companies. Launched in June 2015, the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance is a strong Network of approx. 50 small and medium-sized European biopharmaceutical companies committed by developing innovative products to fend-off […]

Gronigen, The Netherlands. AGILeBiotics BV has raised the next series of investment for the development of novel antibiotics against multidrug-resistant infections. On 18th of July 2018, a deal was closed securing a joined investment from five regional investors, i.e. RUG Houdstermaatschappij BV, Stichting Ir. G.J. Smid Fonds BV, and Hanzepoort BV, Carduso Capital BV and Pharma Connect […]

Supported by the Versneller Innovatieve Ambities (VIA)-subsidy from Samenwerking Noord-Nederland (SNN), AGILeBiotics is developing novel antibiotics for hospital-treated Gram-negative infections. According to the World Health Organization (WHO) and the Infectious Disease Society of America (IDSA) the world is entering the post-antibiotic era, with no therapy option left for patients infected by multidrug-resistant (MDR) pathogen. Without novel […]

AGILeBiotics entered successfully the Health-i-Care program (INTERREG) starting a collaboration with the University Medical Center Groningen (UMCG) and Hospitals in Germany (Muenster and Oldenburg). Health-i-Care is focusing on the development of innovative products and technologies to protect the society from infections caused by resistant microorganisms and to limit the spread of multidrug-resistant bacteria. Thanks to our participation […]